63 research outputs found
Enhanced Platelet Activation Mediates the Accelerated Angiogenic Switch in Mice Lacking Histidine-Rich Glycoprotein
BACKGROUND: The heparin-binding plasma protein histidine-rich glycoprotein (HRG; alternatively, HRGP/HPRG) can suppress tumor angiogenesis and growth in vitro and in vivo. Mice lacking the HRG gene are viable and fertile, but have an enhanced coagulation resulting in decreased bleeding times. In addition, the angiogenic switch is significantly enhanced in HRG-deficient mice. METHODOLOGY/PRINCIPAL FINDINGS: To address whether HRG deficiency affects tumor development, we have crossed HRG knockout mice with the RIP1-Tag2 mouse, a well established orthotopic model of multistage carcinogenesis. RIP1-Tag2 HRG(-/-) mice display significantly larger tumor volume compared to their RIP1-Tag2 HRG(+/+) littermates, supporting a role for HRG as an endogenous regulator of tumor growth. In the present study we also demonstrate that platelet activation is increased in mice lacking HRG. To address whether this elevated platelet activation contributes to the increased pathological angiogenesis in HRG-deficient mice, they were rendered thrombocytopenic before the onset of the angiogenic switch by injection of the anti-platelet antibody GP1bα. Interestingly, this treatment suppressed the increase in angiogenic neoplasias seen in HRG knockout mice. However, if GP1bα treatment was initiated at a later stage, after the onset of the angiogenic switch, no suppression of tumor growth was detected in HRG-deficient mice. CONCLUSIONS: Our data show that increased platelet activation mediates the accelerated angiogenic switch in HRG-deficient mice. Moreover, we conclude that platelets play a crucial role in the early stages of tumor development but are of less significance for tumor growth once angiogenesis has been initiated
Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy
Immunotherapy with IL-2 and anti-CD40 induces the expression of NOS2 in tumor-associated macrophages, and its expression is required for the inhibition of tumor metastasis
The P2X1 receptor and platelet function
Extracellular nucleotides are ubiquitous signalling molecules, acting via the P2 class of surface receptors. Platelets express three P2 receptor subtypes, ADP-dependent P2Y1 and P2Y12 G-protein-coupled receptors and the ATP-gated P2X1 non-selective cation channel. Platelet P2X1 receptors can generate significant increases in intracellular Ca2+, leading to shape change, movement of secretory granules and low levels of αIIbβ3 integrin activation. P2X1 can also synergise with several other receptors to amplify signalling and functional events in the platelet. In particular, activation of P2X1 receptors by ATP released from dense granules amplifies the aggregation responses to low levels of the major agonists, collagen and thrombin. In vivo studies using transgenic murine models show that P2X1 receptors amplify localised thrombosis following damage of small arteries and arterioles and also contribute to thromboembolism induced by intravenous co-injection of collagen and adrenaline. In vitro, under flow conditions, P2X1 receptors contribute more to aggregate formation on collagen-coated surfaces as the shear rate is increased, which may explain their greater contribution to localised thrombosis in arterioles compared to venules within in vivo models. Since shear increases substantially near sites of stenosis, anti-P2X1 therapy represents a potential means of reducing thrombotic events at atherosclerotic plaques
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease
BackgroundThe treatment of chronic hepatitis B (CHB) in patients with
chronic kidney disease (CKD) is based on nucleoside (lamivudine,
telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues
(NAs), but it may be complex and the information is scarce. Entecavir
and tenofovir represent the currently recommended first-line NAs for
NA-naive CHB patients, while tenofovir is the NA of choice for CHB
patients with resistance to nucleosides.
AimTo review the efficacy and safety of NAs in adult CHB patients with
CKD and to provide reasonable recommendations for their optimal
management.
MethodsLiterature search in PubMed/Medline and manual search of relevant
articles, reviews and book chapters.
ResultsNAs are cleared by kidneys and their dosage should be adjusted in
patients with creatinine clearance <50mL/min. There are concerns about
nephrotoxic potential of the nucleotides, particularly adefovir, while
improvements of creatinine clearance have been reported under
telbivudine. Most existing data in CHB patients with CKD are for
lamivudine and, less frequently, for other NAs, mostly entecavir.
Besides CHB, NA should be used in case of immunosuppressive therapy in
any HBsAg-positive patient with CKD including renal transplant (RT)
recipients and in anti-HBs-positive recipients of kidney grafts from
HBsAg-positive donors.
ConclusionsChronic hepatitis B patients with chronic kidney disease
receiving nucleoside analogues should be followed carefully for
treatment efficacy and renal safety. Despite the absence of strong data,
entecavir and telbivudine seem to be the preferred options for
nucleoside analogue-naive CHB patients with chronic kidney disease,
depending on viraemia and severity of renal dysfunction. More studies
are certainly needed in this setting
Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several current regimens, is officially contraindicated. Given that ribavirin free regimens are preferable in CKD, elbasvir/grazoprevir is offered in CHC patients with genotype 1 or 4 and ombitasvir/ paritaprevir and dasabuvir in genotype 1b for 12 wk. Although regimens containing peginterferon with or without ribavirin are officially recommended for patients with CKD and genotype 2, 3, 5, 6, such regimens are rarely used because of their low efficacy and the poor safety and tolerance profile. In this setting, especially in the presence of advanced liver disease, sofosbuvirbased regimens are often used, despite sofosbuvir contraindication. It seems to have good overall safety with only 6% or 3.4% of CKD patients to discontinue therapy or develop serious adverse events without drug discontinuation. In addition, sustained virological response (SVR) rates with sofosbuvir based regimens in CKD patients appear to be comparable with SVR rates in patients with normal renal function. Treatment recommendations for kidney transplant recipients are the same with those for patients with CHC, taking into consideration potential drug-drug interactions and baseline GFR before treatment initiation. This review summarizes recent data on the current management of CHC in CKD patients highlighting their strengths and weaknesses and determining their usefulness in clinical practice. © 2017 Baishideng Publishing Group Inc
Treatment of hepatitis B in patients with chronic kidney disease
Although the prevalence of chronic hepatitis B virus (HBV) infection in
patients with chronic kidney disease remains low in developed countries,
clinicians should be aware of the rationale for treatment in this
setting. This patient population presents particular features and
various complicating conditions requiring special treatment strategies.
Interferon, the standard treatment for HBV infection, has been poorly
tolerated by patients with chronic kidney disease, has presented
relatively low efficacy, and has posed renal transplant recipients under
the risk of acute rejection. The advent of effective nucleos(t)ide
analogs (NAs) has offered the opportunity to minimize the consequences
of HBV infection in HBV-positive patients with chronic kidney disease.
Combination with immunosuppressive agents might be considered in cases
of rapid renal function deterioration and/or severe proteinuria. Among
the newer NAs, entecavir may be preferred, because of its high potency,
high genetic barrier to resistance, and favorable renal safety profile.
However, entecavir presented low efficacy in case of lamivudine or
telbivudine resistance, and thus tenofovir may be a better option in
that setting. All HBsAg-positive candidates should be treated with NAs
before renal transplantation in order to maintain undetectable HBV DNA,
reduce liver fibrosis, and prevent hepatic decompensation after renal
transplantation. This review summarizes updated issues related to
treatment of chronic HBV infection in all categories of population with
chronic kidney disease (those exhibiting HBV-associated glomerular
disease, those treated with hemodialysis, as well as renal transplant
candidates, donors, and recipients)
- …